Tesi sul tema "Prostate cancer"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Vedi i top-50 saggi (tesi di laurea o di dottorato) per l'attività di ricerca sul tema "Prostate cancer".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Vedi le tesi di molte aree scientifiche e compila una bibliografia corretta.
Holt, Jim. "Prostate Cancer". Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/etsu-works/6456.
Testo completoBirtle, A. J. "Prostate specific antigen negative prostate cancer". Thesis, University College London (University of London), 2005. http://discovery.ucl.ac.uk/1444634/.
Testo completoHolt, Jim, e Fereshteh Gerayli. "Prostate Cancer Screening". Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/etsu-works/6471.
Testo completoLexander, Helena. "Protein expression in prostate cancer /". Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-617-4/.
Testo completoLundberg, Kajsa. "On immunotherapy against prostate cancer". Stockholm : Karolinska institutet, 2010. http://diss.kib.ki.se/2010/978-91-7409-805-1/.
Testo completoWirth, Manfred P., e Michael Fröhner. "Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program". Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133551.
Testo completoDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
Wirth, Manfred P., e Michael Fröhner. "Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program". Karger, 2003. https://tud.qucosa.de/id/qucosa%3A27515.
Testo completoDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
Storey, Dawn J. "Fatigue and prostate cancer". Thesis, University of Edinburgh, 2008. http://hdl.handle.net/1842/29383.
Testo completoHendrickx, Wouter R. L. "Selenium and prostate cancer". Thesis, University of East Anglia, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.588614.
Testo completoGrönberg, Henrik. "Prostate cancer : epidemiological studies". Doctoral thesis, Umeå universitet, Onkologi, 1995. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-96894.
Testo completoHärtill 5 uppsatser
digitalisering@umu
Wirth, Manfred P., e Oliver W. Hakenberg. "Brachytherapy for Prostate Cancer". Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133901.
Testo completoWirth, Manfred P., e Oliver W. Hakenberg. "Brachytherapy for Prostate Cancer". Karger, 1999. https://tud.qucosa.de/id/qucosa%3A27547.
Testo completoHerrera, Maria Lourdes C. "The expression of various growth factors in the normal human prostate, benign prostatic hyperplasia, and prostate carcinoma". Thesis, Hong Kong : University of Hong Kong, 1996. http://sunzi.lib.hku.hk/hkuto/record.jsp?B1754628X.
Testo completoQuintal, Maisa Momesso de. "Cancer de prostata : estudo da extensão tumoral em prostatectominas radicais". [s.n.], 2007. http://repositorio.unicamp.br/jspui/handle/REPOSIP/308452.
Testo completoDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-09T01:30:27Z (GMT). No. of bitstreams: 1 Quintal_MaisaMomessode_M.pdf: 3825980 bytes, checksum: 7250ae540bacae85643a8842909d79d6 (MD5) Previous issue date: 2007
Resumo: No estadiamento TNM 1997, os tumores de próstata órgão-confinados eram subdivididos em dois grupos: pT2a (unilaterais) e pT2b (bilaterais). Em 2002, o sistema TNM reclassificou os tumores em três grupos: pT2a (envolvimento de menos da metade de um lobo), pT2b (mais da metade de um lobo), e pT2c (envolvimento bilateral). Estudos recentes questionam a verdadeira existência de tumores pT2b, assim como diferenças relacionadas à progressão bioquímica pós-prostatectomia radical entre os estádios pT2a e pT2c. Os objetivos deste trabalho são: avaliar a extensão tumoral em espécimes de prostatectomia radical, relacionando-a com graduação histológica de Gleason, comprometimento de margens cirúrgicas, estádio clínico e patológico, PSA pré-operatório e tempo de progressão bioquímica pós-prostatectomia radical; comparar tumores localizados com comprometimento bilateral (T2c) com tumores órgão-confinados com comprometimento unilateral (pT2a) quanto aos mesmos parâmetros e verificar a existência real do estádio patológico pT2b. Foram estudados 230 homens submetidos à prostatectomia radical no período de janeiro de 1997 a julho de 2005 na Universidade Estadual de Campinas. Os espécimes cirúrgicos foram totalmente incluídos para exame histológico. A extensão tumoral foi avaliada utilizando-se um sistema de contagem de pontos. Os espécimes cirúrgicos foram estadiados segundo os critérios do TNM 2002. Os valores séricos de PSA = 0,4 ng/ml foram considerados como progressão bioquímica tumoral. Os dados foram analisados estatisticamente utilizando-se o teste de Mann-Whitney para comparação de amostras independentes e o teste exato de Fisher para avaliação de diferenças entre proporções. Foram considerados significantes os valores de p = 0,05. Para avaliação do tempo de progressão bioquímica pós-prostatectomia radical utilizou-se o produto limite de Kaplan-Meier. Utilizando os critérios TNM 2002, 29 pacientes (12,7%) eram pT2a; 139 (61,3%) eram pT2c; 30 (13,7%) eram pT3a e 28 (12,3%) eram pT3b. O mínimo e o máximo de pontos totais obtidos em tumores que envolviam apenas um lobo prostático foi de 192 e de 368 pontos, respectivamente; o maior tumor unilateral mostrou 68 pontos positivos (menos da metade do valor mínimo de pontos totais). Não foi constado nenhum caso onde a neoplasia prostática comprometesse mais da metade de um lobo, sem envolver o lobo contralateral (pT2b). A extensão tumoral apresentou relação significante e direta com PSA pré-operatório, graduação histológica de Gleason, margens cirúrgicas positivas e estádios clínico e patológico, mas não com o tempo de progressão bioquímica pós-prostatectomia radical. Não houve diferenças entre os pacientes com estádios pT2a e pT2c com relação ao PSA pré-operatório, contagem final de Gleason e tempo de progressão bioquímica, com exceção do comprometimento das margens cirúrgicas. Há relação da extensão tumoral em espécimes cirúrgicos de prostatectomia radical com PSA pré-operatório, graduação histológica de Gleason, margens cirúrgicas positivas e estádio patológico. A extensão tumoral isoladamente não parece influenciar o tempo de progressão bioquímica pós-prostatectomia radical. Este estudo questiona a real existência do estádio pT2b (tumores unilaterais que ocupam mais da metade de um lobo). Não há diferenças significativas quanto ao tempo de progressão bioquímica pós-prostatectomia radical entre os estádios patológicos pT2a e pT2c. Esses achados apóiam autores que defendem a não subdivisão do estádio pT2
Abstract: In the 1997 TNM staging system, confined-organ prostate tumors were classified in two groups: pT2a (unilateral involvement) and pT2b (bilateral involvement). In 2002, TNM staging system reclassified those tumors in three groups: pT2a (less than one half of one lobe involvement), pT2b (more than one half of one lobe involvement) and pT2c (bilateral involvement). Recent studies put in question the existence of a real pT2b tumor as well as a difference related to biochemical progression after radical prostatectomy between pT2a and pT2c tumors. The aim of this study is to verify the real existence of pT2b and evaluate tumor size comparing to Gleason score, positive surgical margins, clinical and pathological stage, preoperative PSA and time to biochemical progression after radical prostatectomy. Besides that, compare bilateral tumors (pT2c) with unilateral ones (pT2a) according to the same parameters. A total of 230 men were submitted to radical retropubic prostatectomy from July 1997 to July 2005 at Universidade Estadual de Campinas. All the surgical specimens were evaluated by complete embedding and whole mount processing. Tumor extent was evaluated through a point-count method. The surgical specimens were staged according to 2002 TNM staging system. The serum values of PSA= 0,4 ng/ml were considered biochemical progression. Mann-Whitney¿s test and Fisher¿s exact test were used to compare independent samples and different proportions. p = 0,05 was considered significant. Time to PSA progression was studied using the Kaplan-Meier¿s product limit survival estimates. Using the 2002 TNM criteria, 29 patients (12,7%) were pT2a; 139 (61,3%) were pT2c; 30 (13,7%) were pT3a and 28 (12,3%) were pT3b. The minimum and maximum total points obtained in unilateral tumors were 192 and 368 points, respectively; the biggest unilateral tumor showed 68 positive points (less than half the minimum of total point count). This study found no pT2b tumors (unilateral tumors involving greater than one-half of one prostatic lobe). Tumor extent was directly related to preoperative PSA, Gleason score, positive surgical margins, clinical and pathological stage. Alone, tumor extent does not seem to influence biochemical progression. Comparing pT2a with pT2c, there were no differences in preoperative PSA, Gleason score and biochemical progression, except positive surgical margins. There is a connection of tumor extent in radical prostatectomy specimens with preoperative PSA, Gleason score, positive surgical margins and pathological stage. Tumor extent does not seem to influence time of biochemical progression after retropubic radical prostatectomy. This study puts in question the real existence of pT2b pathological stage (unilateral tumors involving greater than one-half of one prostatic lobe). There are no significant differences between pT2a and pT2c patients in time to biochemical progression after retropubic radical prostatectomy. These findings support authors who question the subdivision of pathological stage pT2
Mestrado
Anatomia Patologica
Mestre em Ciências Médicas
Wiklund, Fredrik. "Genetic epidemiology of prostate cancer". Doctoral thesis, Umeå : Univ, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-281.
Testo completoMatar, Corine. "Métabolisme oxydatif et mitochondrial des cellules cancéreuses de prostate". Thesis, Paris Est, 2011. http://www.theses.fr/2011PEST0094.
Testo completoKnight, Kellie Ann. "Daily Image Guided Radiation Therapy for Prostate Cancer: An assessment of treatment plan reproducibility". Thesis, The University of Sydney, 2006. http://hdl.handle.net/2123/1628.
Testo completoKnight, Kellie Ann. "Daily Image Guided Radiation Therapy for Prostate Cancer: An assessment of treatment plan reproducibility". University of Sydney, 2006. http://hdl.handle.net/2123/1628.
Testo completoIt is well documented that for prostate cancer patients undergoing radiation therapy there is a correlation between target volume displacement and changes in bladder and rectal volumes. However, these studies have used a methodology that has captured only a subset of all treatment positions. This research used daily Computer Tomography (CT) imaging to comprehensively assess organ volumes, organ motion and their effect on dose, something that has never been performed previously, thus adding considerably to the understanding of the topic. Daily CT images were obtained using a Siemens Primus Linear Accelerator equipped with an in-room Somatom CT unit in the accelerator suite, marketed as ‘Primatom’, to accurately position the patient prior to treatment delivery. The internal structures of interest were contoured on the planning workstation by the investigator. The daily volume and location of the organs were derived from the computer to assess and analyse internal organ motion. The planned dose distribution was then imported onto the treatment CT datasets and used to compare the planned dose to i) the actual isocentre, where the isocentre was actually placed for that fraction, ii) the uncorrected isocentre, by un-doing any on-line corrections performed by the treatment staff prior to treatment delivery, and iii) the future isocentre, by placing the isocentre relative to internal organ motion on a daily basis. The results of this study did not confirm a statistically significant decrease in rectum volumes over time (hypothesis 1), however large fluctuations in bladder volume were confirmed (hypothesis 2). Internal organ motion for the rectum and bladder was demonstrated to be related to organ filling. Ideal planning volumes for these organs have been reported to minimise systematic and random uncertainty in the treatment volumes. An observed decrease in prostate volume over time, a systematic uncertainty in the location of the prostate at the time of the planning CT scan and a significant relationship between prostate centre of volume and rectum and bladder volumes has resulted in a recommendation that patients should be re-scanned during treatment to ensure appropriate clinical target volume coverage. A significant relationship between rectal and bladder volumes and the dose delivered to these organs was found (hypothesis 3). The dose delivered to the planning target volume was not related to the rectal or bladder volumes, although it was related to the motion of these organs. Despite these results only minimal effects on the dose delivered to any of the three isocentres occurred, indicating that the planned dose was accurately delivered using the methodology presented here (hypothesis 4). However the results do indicate that the patient preparation instructions need to be improved if margins are to be reduced in the future. It is unrealistic to assume that Image Guided Radiation Therapy will ever become routine practice due to infrastructure costs and time limitations. This research will inform radiation therapy centres of the variables associated with prostate cancer treatment on a daily basis, something that has never before been realistically achievable. As a result centres will be able to devise protocols to improve treatment outcomes.
Ambrosini, Gina L. "Dietary risk factors for prostate cancer and benign prostatic hyperplasia". University of Western Australia. School of Population Health, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0135.
Testo completoKhan, Humera. "Determinants of prostate cancer : the Birmingham Prostatic Neoplasms Association study". Thesis, University of Birmingham, 2011. http://etheses.bham.ac.uk//id/eprint/3170/.
Testo completoHarper, Curt E. "Prostate cancer chemoprevention with genistein and resveratrol in models of spontaneously developing prostate cancer". Thesis, Birmingham, Ala. : University of Alabama at Birmingham, 2007. https://www.mhsl.uab.edu/dt/2007p/harper.pdf.
Testo completoDowning, David G. "Cancer-related Masculine Threat, Body Compassion, and Prostate-specific Functioning in Prostate Cancer Patients". Xavier University / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=xavier1557162136506447.
Testo completoSingh, Rashmi. "Genetic predisposition to prostate cancer". Thesis, Institute of Cancer Research (University Of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.416575.
Testo completoMohamed, M. "Epigenetic biomarkers in prostate cancer". Thesis, Queen's University Belfast, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.426926.
Testo completoThorn, Shirley A. "Prostate cancer, the screening conundrum". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape17/PQDD_0003/MQ32265.pdf.
Testo completoLindmark, Fredrik. "Prostate cancer and inflammatory genes". Doctoral thesis, Umeå : Strålningsvetenskaper, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-667.
Testo completoSorreta, Arianne G. "Docosahexaenoic acid and prostate cancer". abstract and full text PDF (free order & download UNR users only), 2007. http://0-gateway.proquest.com.innopac.library.unr.edu/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:1446441.
Testo completoRomanuik, Tammy Lee. "Gene expression in prostate cancer". Thesis, University of British Columbia, 2008. http://hdl.handle.net/2429/5313.
Testo completoCollin, Simon Michael. "Folate metabolism and prostate cancer". Thesis, University of Bristol, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.541606.
Testo completoMavrou, Athina. "Targeting angiogenesis in prostate cancer". Thesis, University of Bristol, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.654119.
Testo completoWirth, Manfred P., e Oliver W. Hakenberg. "Curative Treatment of Prostate Cancer". Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133890.
Testo completoDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
Adamson, Andrew Stephen. "Procoagulants, coagulopathy and prostate cancer". Thesis, University of Southampton, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.316445.
Testo completoOxley, Jonathan David. "Prognostic indicators in prostate cancer". Thesis, Queen Mary, University of London, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.394837.
Testo completoRatan, Hari Lakshmi. "Combinatorial chemoprevention of prostate cancer". Thesis, University of Leicester, 2004. http://hdl.handle.net/2381/29474.
Testo completoWirth, Manfred P., e Oliver W. Hakenberg. "Curative Treatment of Prostate Cancer". Karger, 1999. https://tud.qucosa.de/id/qucosa%3A27546.
Testo completoDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
Klossner, Daniel Patrick. "Improving cryosurgical ablation of advanced state prostate cancer through identification of molecular targets in a prostrate cancer cell model". Diss., Online access via UMI:, 2007.
Cerca il testo completoChang, Ching-Jey George. "Prostate, benign hypertrophy and prostatic carcinoma - a study of cell biology of prostate and chemotherapy for prostatic hypertrophy and prostatic cancer /". The Ohio State University, 1994. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487856906256116.
Testo completoMENCACCI, CECILIA. "Identification of candidate prostate cancer biomarkers in prostate needle biopsy". Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2009. http://hdl.handle.net/2108/1142.
Testo completoProstate cancer is the most common cancer among men and it is a significant cause of morbidity and mortality worldwide. Screening for prostate specific antigen has led to earlier detection of prostate cancer. However PSA is neither tissue specific. Thus the serum PSA screening is characterized by poor specificity as well as poor sensitivity. This low specificity of PSA is a reason of marker improvement. Therefore it is of prime interest to develop clinical markers with a superior specificity for prostate cancer lesions for use in the initial diagnosis. Characterization of gene expression profiles that molecularly distinguish prostatic neoplasms may identify genes involved in prostate carcinogenesis. For this study, we determined the expression level of ODC1, DPP4, IMPDH1, IMPDH2, ZIP1, ZIP2, ZIP3 & ZIP4 by means of Real-Time PCR (qPCR). Quantitative detection of human genes was performed with a Light-Cycler 1.5 Instrument. Prostate tissue specimens were obtained from 30 patients undergoing prostate needle biopsy. These included 14 patients who were diagnosed for Adenocarcinoma, 14 who had a diagnosis of benign prostate hyperplasia (BPH), and 2 of prostatic intraepithelial neoplasia (PIN). The serum PSA levels of these patients were determined and all patients had a range between 2,68ng/ml and 100ng/ml (mean PSA value=13,95ng/ml). The mean age of the selected patients was between 43 and 80 years (mean age= 65,3years) and Gleason score between 0 and 8 ( mean score =3,1). Our results clearly establish that Zip1, Zip2, and Zip3 mRNA are down regulated in malignant prostate glands and up regulated in BPH. This is the first report that identifies the expression of Zip1, Zip2, Zip3 and Zip4 in human prostate needle biopsy. The down regulation of these transporters in the malignant cells is essential for the cellular depletion of zinc to prevent the anti tumor effects of zinc. These findings are consistent with the concept that Zip1, Zip2 and Zip3 are tumor-suppressor genes in prostate cancer. The identification of new prostate cancer specific genes such as ZIP genes would represent a considerable advance in the improvement of diagnostics tests for prostate cancer.
Amin, Al Olama Seyed Ali. "Genetic epidemiology of prostate cancer statistical analyses of genome-wide association studies of prostate cancer". Thesis, University of Cambridge, 2013. https://www.repository.cam.ac.uk/handle/1810/252290.
Testo completoTaylor, Michael Dennis. "Prostate cancer clinical practice guidelines clinical and economic outcomes /". [Gainesville, Fla.] : University of Florida, 2005. http://purl.fcla.edu/fcla/etd/UFE0010098.
Testo completoTypescript. Title from title page of source document. Document formatted into pages; contains 99 pages. Includes Vita. Includes bibliographical references.
Li, Xing. "Novel brachytherapy techniques for cervical cancer and prostate cancer". Diss., University of Iowa, 2015. https://ir.uiowa.edu/etd/1682.
Testo completoWalker, Sandra. "Prostate cancer support groups an evaluation /". Australasian Digital Thesis Program, 2005. http://adt.lib.swin.edu.au/public/adt-VSWT20060905.085536.
Testo completoSubmitted in fulfilment of the requirements for the degree of Professional Doctorate Health Psychology, Department of Psychology, Swinburne University of Technology - 2005. Typescript. Includes bibliographical references (p. 151-159).
Sridhar, Gayathri. "Meta-analysis: Racial Disparities in Prostate Cancer Survival and Case-Control Study: Association between Family History of Cancers, Obesity and Prostate Cancer". VCU Scholars Compass, 2009. http://scholarscompass.vcu.edu/etd/1758.
Testo completoBouffard, Elise. "Synthèse de glyconanovecteurs pour la thérapie photodynamique des cancers de la prostate". Thesis, Montpellier 2, 2014. http://www.theses.fr/2014MON20231.
Testo completoThe cation independant mannose 6-phosphate receptor (CI-M6PR) allows the endocytosis and the transport of mannose 6-phosphate (M6P) bearing molecules toward the lysosomes. The CI-M6PR, which is overexpressed by prostate cancer cells, is a target of interest to increase drug delivery in these cells. However, M6P is sensitive to degradation by phosphatases in the serum. To increase both the stability and the affinity for the CI-M6PR, we synthesized new M6P isosteric analogs. These analogs are functionnalized at the anomeric position to permit their grafting on mesoporous silica nanoparticles incorporating a photosensitizer. The biological evaluation demonstrated an affinity gain of the new analogs for the CI-M6PR as well as an increase of the efficacy of the nanoparticles functionnalized with these analogs for the in vitro photodynamic therapy of cancer prostate cells
Orakpo, W. Nnamdi. "Does Prostate Cancer Begin in the Prostate? Key Predictors of Diagnosis". Thesis, University of North Texas, 2011. https://digital.library.unt.edu/ark:/67531/metadc84262/.
Testo completoEsser, Alison K. "The role of dystroglycan in the prostate epithelium and prostate cancer". Diss., University of Iowa, 2011. https://ir.uiowa.edu/etd/2696.
Testo completoLawson, Deborah A. "Prostate cancer screening practices of Missouri physicians /". free to MU campus, to others for purchase, 1998. http://wwwlib.umi.com/cr/mo/fullcit?p9901254.
Testo completoPowolny, Anna Aleksandra. "Diet, nutrition and prostate cancer angiogenesis". Columbus, Ohio : Ohio State University, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1148992965.
Testo completoRodgers, Lisa. "The phosphagen system in prostate cancer". Thesis, University of Glasgow, 2017. http://theses.gla.ac.uk/8520/.
Testo completoYoung, James Graham. "Gene & immunotherapy of prostate cancer". Thesis, University of Birmingham, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.289297.
Testo completo